Cargando…

MicroRNA signature in classical Hodgkin lymphoma

Classical Hodgkin lymphoma (cHL) is one of the most prevalent lymphomas with a unique cell composition compared to other lymphoma entities. Rare, malignant Hodgkin and Reed-Sternberg (HRS) cells embedded with an extensive but ineffective immune infiltration were previously characterized by a large n...

Descripción completa

Detalles Bibliográficos
Autores principales: Paczkowska, Julia, Giefing, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032569/
https://www.ncbi.nlm.nih.gov/pubmed/33544339
http://dx.doi.org/10.1007/s13353-021-00614-7
_version_ 1783676234227515392
author Paczkowska, Julia
Giefing, Maciej
author_facet Paczkowska, Julia
Giefing, Maciej
author_sort Paczkowska, Julia
collection PubMed
description Classical Hodgkin lymphoma (cHL) is one of the most prevalent lymphomas with a unique cell composition compared to other lymphoma entities. Rare, malignant Hodgkin and Reed-Sternberg (HRS) cells embedded with an extensive but ineffective immune infiltration were previously characterized by a large number of genetic and epigenetic alterations. Recently, microRNA profiling studies highlighted the importance of small non-coding RNA in cHL. This review summarizes available literature data and provides a detailed comparison of four studies where cHL cell lines and microdissected HRS cells were used. Several microRNAs were found to be consistently up- (let-7-f, mir-9, mir-21, mir-23a, mir-27a, mir-155, and mir-196a) or downregulated (mir-138 and mir-150) in cHL. These deregulated microRNAs are involved in the processes crucial for cHL pathogenesis, such as impaired B cell development (mir-9, mir-150, and mir-155), NFκB hyperactivation (mir-155 and mir-196a), and immune evasion (mir-138). Therefore, the deregulation of microRNA expression can be considered a complementary mechanism to genetic alterations promoting lymphomagenesis. Moreover, the expression of let-7f, mir-9 and mir-27a is specific for cHL and can serve as a biomarker to distinguish this lymphoma from other B cell lymphomas. However, additional in-depth and high throughput analysis of microRNA expression in HRS cells is necessary to decipher the complete picture of microRNA in cHL. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13353-021-00614-7.
format Online
Article
Text
id pubmed-8032569
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-80325692021-04-27 MicroRNA signature in classical Hodgkin lymphoma Paczkowska, Julia Giefing, Maciej J Appl Genet Human Genetics • Mini-Review Classical Hodgkin lymphoma (cHL) is one of the most prevalent lymphomas with a unique cell composition compared to other lymphoma entities. Rare, malignant Hodgkin and Reed-Sternberg (HRS) cells embedded with an extensive but ineffective immune infiltration were previously characterized by a large number of genetic and epigenetic alterations. Recently, microRNA profiling studies highlighted the importance of small non-coding RNA in cHL. This review summarizes available literature data and provides a detailed comparison of four studies where cHL cell lines and microdissected HRS cells were used. Several microRNAs were found to be consistently up- (let-7-f, mir-9, mir-21, mir-23a, mir-27a, mir-155, and mir-196a) or downregulated (mir-138 and mir-150) in cHL. These deregulated microRNAs are involved in the processes crucial for cHL pathogenesis, such as impaired B cell development (mir-9, mir-150, and mir-155), NFκB hyperactivation (mir-155 and mir-196a), and immune evasion (mir-138). Therefore, the deregulation of microRNA expression can be considered a complementary mechanism to genetic alterations promoting lymphomagenesis. Moreover, the expression of let-7f, mir-9 and mir-27a is specific for cHL and can serve as a biomarker to distinguish this lymphoma from other B cell lymphomas. However, additional in-depth and high throughput analysis of microRNA expression in HRS cells is necessary to decipher the complete picture of microRNA in cHL. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13353-021-00614-7. Springer Berlin Heidelberg 2021-02-05 2021 /pmc/articles/PMC8032569/ /pubmed/33544339 http://dx.doi.org/10.1007/s13353-021-00614-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Human Genetics • Mini-Review
Paczkowska, Julia
Giefing, Maciej
MicroRNA signature in classical Hodgkin lymphoma
title MicroRNA signature in classical Hodgkin lymphoma
title_full MicroRNA signature in classical Hodgkin lymphoma
title_fullStr MicroRNA signature in classical Hodgkin lymphoma
title_full_unstemmed MicroRNA signature in classical Hodgkin lymphoma
title_short MicroRNA signature in classical Hodgkin lymphoma
title_sort microrna signature in classical hodgkin lymphoma
topic Human Genetics • Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032569/
https://www.ncbi.nlm.nih.gov/pubmed/33544339
http://dx.doi.org/10.1007/s13353-021-00614-7
work_keys_str_mv AT paczkowskajulia micrornasignatureinclassicalhodgkinlymphoma
AT giefingmaciej micrornasignatureinclassicalhodgkinlymphoma